COVID-19 Stroke Apical Lung Examination Study: A Diagnostic and Prognostic Imaging Biomarker in Suspected Acute Stroke


AJNR Am J Neuroradiol  published online 17 September 2020
http://www.ajnr.org/content/early/2020/09/17/ajnr.A6832
COVID-19 Stroke Apical Lung Examination Study: A Diagnostic and Prognostic Imaging Biomarker in Suspected Acute Stroke


ABSTRACT

BACKGROUND AND PURPOSE: Diagnosis of coronavirus disease 2019 (COVID-19) relies on clinical features and reverse-transcriptase polymerase chain reaction testing, but the sensitivity is limited. Carotid CTA is a routine acute stroke investigation and includes the lung apices. We evaluated CTA as a potential COVID-19 diagnostic imaging biomarker.

MATERIALS AND METHODS: This was a multicenter, retrospective study (n = 225) including CTAs of patients with suspected acute stroke from 3 hyperacute stroke units (March-April 2020). We evaluated the reliability and accuracy of candidate diagnostic imaging biomarkers. Demographics, clinical features, and risk factors for COVID-19 and stroke were analyzed using univariate and multivariate analysis. In contrast, all other contemporaneous demographic, clinical, and imaging features available at CTA were not diagnostic for COVID-19. The presence of apical ground-glass opacification was an independent predictor of increased 30-day mortality (18.0% versus 5.7%, \( P = .017 \); hazard ratio = 3.51; 95% CI, 1.42–8.66; \( P = .006 \)).

CONCLUSIONS: We identified a simple, reliable, and accurate COVID-19 diagnostic and prognostic imaging biomarker obtained from CTA lung apices: the presence or absence of ground-glass opacification. Our findings have important implications in the management of patients presenting with suspected stroke through early identification of COVID-19 and the subsequent limitation of disease transmission.

ABBREVIATIONS: BSTI = British Society of Thoracic Imaging; COVID-19 = coronavirus disease 2019; GGO = ground-glass opacification; IRR = interrater reliability; RT-PCR = reverse-transcriptase polymerase chain reaction; SARS-CoV-2 = Severe Acute Respiratory Syndrome coronavirus 2

The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) was given pandemic status by the World Health Organization in March 2020. When symptomatic, coronavirus disease 2019 (COVID-19) typically causes mild, self-limiting respiratory features. However, a severe lower respiratory and multisystem disease may occur, necessitating hospitalization. Approximately 6.0% of patients with COVID-19 die, and 12% require intensive care support. Symptoms alone are insufficient for a diagnosis due to a high prevalence of asymptomatic carriers and a variable presymptomatic incubation period (2–14 days). The diagnostic reference standard is the reverse-transcriptase polymerase chain reaction
(RT-PCR) test using nasopharyngeal swabs or bronchial secretions, but it is constrained by a sensitivity of 60%–73%.

However, a dedicated chest CT is likely to be more sensitive than RT-PCR for COVID-19, which, according to a study of 1014 patients, has a sensitivity of 88% compared with 59%. A dedicated chest CT for COVID-19 diagnosis is not feasible or recommended in patients suspected of having COVID-19. Furthermore, in many health care systems, including in the United States and the United Kingdom, the routine use of chest CT for COVID-19 diagnosis is not feasible or recommended in patients suspected of having COVID-19.

The classic COVID-19 appearance on chest CT is ground-glass opacification (GGO), with a predilection for the lower lobes and posterior segments. While lung apices are included on carotid CTA during acute-stroke investigations, they may be overlooked when vascular causes of stroke are the focus. Abdominal CT has shown lower lobe pulmonary abnormalities consistent with COVID-19 in those with a low clinical suspicion for infection. However, there is no evidence determining the prevalence of such findings in the lung apices, nor the relationship between the extent of lung included on CTA and diagnostic accuracy, nor whether COVID-19 diagnostic imaging biomarkers can be obtained from CTA. This is particularly pertinent because COVID-19 appears to be associated with TIAs and strokes.

This multicenter, observational study aimed to derive diagnostic imaging biomarkers using CTA to facilitate early identification of patients with COVID-19.

MATERIALS AND METHODS

Study Design
The National Health Research Authority and Research Ethics Committee approved this study. The authors declare no conflicts of interest. There is no overlap in subjects from prior publications.

We identified, retrospectively, adult patients (18 years of age or older) undergoing a CT of the head and CTA for acute-stroke investigations at 3 hyperacute stroke units, King’s College Hospital, Princess Royal University Hospital, and University College London Hospitals from March 25, 2020, to April 24, 2020 (corresponding to the time and location of the United Kingdom COVID-19 epicenter). We excluded CTAs that were nondiagnostic or performed for nonacute reasons. For reference, a control group of the same number of patients undergoing acute-stroke investigations during the same period in 2019 was also reviewed.

Imaging
The acute-stroke imaging protocol consisted of noncontrast CT of the head followed by a craniocevical arterial phase acquisition after intravenous injection of 50 mL of iohexol, 647 mg/mL (5 mL/s) (Omnipaque 300; GE Healthcare); 1 mL/kg of iohexol, 647 mg/mL (4 mL/s) (Omnipaque 300; GE Healthcare); or 50 mL of iohexol, 755 mg/mL (4 mL/s) (Omnipaque 350; GE Healthcare). The scans were performed on multidetector CT scanners (Optima 660, 64-section; Discovery 750, 128-section [both GE Healthcare]; Aquilion Prime 320 slice [Toshiba]; Definition AS, 128-section [Siemens]).

The main scanning parameters were as follows for CT of the head/CTA studies respectively: tube voltage = 140 kV (peak)/100 kVp; automatic tube current modulation = 100–515/5–480 mAs; pitch = 0.55/0.8 mm; matrix = 512 × 512 (both); section thickness = 5/0.625 mm; FOV = 230 × 230 mm (both). All images were then reconstructed with a section thickness of 0.625 mm, with the same increments.

Data Collection
Blinded to radiologic findings, we obtained demographic and clinical data from electronic medical records (Sunrise; Epic Electronic Health Records). Data included respiratory and stroke clinical features on admission, risk factors for stroke and COVID-19 transmission, and clinical outcome. The details of RT-PCR testing were also recorded (Altona Diagnostics, Hologic, and Abbott Laboratories).

All imaging examinations were independently evaluated by fellowship-trained neuroradiologists, (J.S., F.B., S.S., A.M.F., with 7, 6, and 3 years’ experience, respectively), blinded to the clinical data and the RT-PCR results. Readers analyzed the images on the PACS using source images, maximum intensity projections, and multiplanar reformattting. The coronal depth of the lung apices imaged was measured for both lungs. CTA studies were reviewed in the axial plane using lung window and vascular window settings (window width/level, 1500/-500 Hounsfield units [HU] and 600/150 HU, respectively).

To find diagnostic imaging biomarkers for COVID-19 that would be easy to apply by radiologists who are not specialized in chest radiology, we evaluated the presence of GGO and any other pulmonary finding within the lung apices on CTA. Cases in which GGO was unequivocally due to dependency, breathing artifacts, or expiratory change were excluded. GGO was also subclassified as focal or diffuse, central or peripheral, and unilateral or bilateral.

We also used categories based on the British Society of Thoracic Imaging (BSTI) COVID-19 Guidance for Reporting Radiology (a nonvalidated guideline implemented at the start of COVID-19; On-line Table 1) (https://www.bsti.org.uk/media/resources/files/BSTI_COVID-19_Radiology_Guidance_version_2_16.03.20.pdf). All readers, along with a thoracic radiologist with 18 years’ experience as a reference standard reader, gave a 3-point likelihood score to rate the lesions (COVID-19-typical lesions, indeterminate lesions, and non-COVID-19 lesions).

Statistics
Descriptive statistics were used to summarize data.

We determined the agreement between measures from multiple independent readers using the Fleiss κ coefficient with standard interpretation guidelines. We selected features for which there was “substantial” (0.61–0.80) or “almost perfect” agreement (0.81–1.0) for further accuracy evaluation using confusion matrix outcomes.

Comparative statistics were used to analyze differences in 2020 and 2019 baseline data. Normality of distributions was assessed using the Shapiro-Wilk test. For univariate analyses, we used χ² tests for categoric variables (or Fisher exact tests when cell frequency was <5) and the Student t test for continuous data (or the Mann-Whitney U test for non-normal distributions). With regard to the number of events in our study, we were limited by the number of confounders we could include in the multivariate logistic regression, so we followed the recommendation that a minimum
of 10 events per variable be incorporated to maintain model validity. 

We also evaluated the relationship between the presence of apical GGO and a craniocaudal measurement of the lung included on the coronal CT scan, by calculating the point biserial correlation coefficient. GGO was tested as a predictor of survival using a multivariate Cox proportional hazards regression model. Statistical analysis was performed using SPSS Statistics (Version 26.0; IBM).

RESULTS
Baseline Characteristics
Two hundred twenty-five patients were identified during the 2020 COVID-19 period (On-line Figure A). The patients’ baseline characteristics in 2019 and 2020 were described and compared (On-line Table 2). The mean hospital stay of survivors was shorter in 2020 (9.7 versus 4.4 days; \( P = .04 \)). There was no overall difference in clinical and imaging stroke-severity scores, thrombolysis, thrombectomy, or mortality rates.

Imaging Characteristics
We observed apical GGO in 22.2% (50/225) of patients in 2020. In 2020, when using the descriptive COVID-19 CT grading system, 28.0% (14/50) of those with GGO were rated as COVID-19-typical; 24.0% (12/50), indeterminate; and 48.0% (24/50), non-COVID-19; all features were more common than in 2019 (\( P < .001 \)) (Fig 1).

To ensure that these potential diagnostic imaging biomarkers were reliable, we determined the interobserver agreement of these CTA findings in the setting of a neuroradiology department. The interrater reliability (IRR) was almost perfect (Fleiss \( \kappa = 0.81; 95\% \text{ CI}, 0.68–0.95 \)) for rating of the presence or absence of apical GGO (On-line Table 3). By means of a descriptive COVID-19 CT grading system, the IRR among 4 neuroradiologist raters was substantial (Fleiss \( \kappa = 0.74; 95\% \text{ CI}, 0.64–0.84 \)). The IRR was lower but remained substantial when adding a reference standard rating (Fleiss \( \kappa = 0.65; 95\% \text{ CI}, 0.60–0.71 \)). When we reduced the 3-point scale to a 2-point scale (COVID-19-typical/indeterminate versus non-COVID-19/normal), the IRR improved to almost perfect among the neuroradiologists (Fleiss \( \kappa = 0.88; 95\% \text{ CI}, 0.75–1.0 \)), and it also improved when adding a reference standard rating (Fleiss \( \kappa = 0.79; 95\% \text{ CI}, 0.71–0.86 \)). Nonetheless, the IRR was highest among neuroradiologist raters for the well-defined tasks of looking at apical GGO subfeatures: focal versus nonfocal (diffuse/normal), bilateral versus nonbilateral (unilateral/normal), and peripheral versus nonperipheral (central/normal), which gave Fleiss \( \kappa \) scores of 0.90 (95% CI, 0.80–1.00), 0.98 (95% CI, 0.87–1.0), and 0.87 (95% CI, 0.78–0.98) respectively.

RT-PCR Cohort Characteristics
Forty-seven percent (106/225) of patients underwent RT-PCR testing, and 26.4% (28/106) had positive findings (On-line Table 4). A test was performed at or immediately before CTA in 44.3% (47/106) of patients; findings in 23.4% (11/47) were positive, but the result was available at the time of CTA in only 14.9% (7/47). The patients with positive findings on RT-PCR had a higher mortality rate (28.6% [8/28] versus 7.7% [6/78], \( P = .009 \)) and received intravenous thrombolysis more often (32.1% [9/28] versus 12.8% [10/78], \( P = .02 \)). There was no difference in any demographic or clinical characteristics, with the exception of oxygen saturation, which was lower in patients with a positive RT-PCR result (\( P = .03 \)). In contrast, all imaging biomarkers were seen more commonly in patients with a positive RT-PCR result (\( P < .001 \)). We determined the diagnostic accuracy of these imaging biomarkers for SARS-CoV-2 using RT-PCR as the reference standard, having shown their reliability (interrater analyses above).

We measured the sensitivity, specificity, and positive predictive and negative predictive values. The presence of GGO was the most sensitive biomarker, and the descriptive COVID-19 CT grading system using a 2-point scale was the most specific (Table 1). Because the presence of GGO was the most sensitive diagnostic imaging biomarker and the simplest for a clinician to use with high interrater reliability, we incorporated this variable into a multivariate analysis (Table 2), comparing it with other clinical and imaging features immediately available on hospital admission. We included all features in which univariate analysis (On-line Table 4) showed group comparison differences of \( P \leq .05 \). Only the presence of GGO showed an increased likelihood of a positive RT-PCR result (OR = 11.65; 95% CI, 4.14–32.78; \( P < .001 \)).

In summary, radiologists who were not specialized in chest radiology evaluated the presence or absence of apical GGO. This measurement had a very high IRR (Fleiss \( \kappa = 0.81; 95\% \text{ CI}, 0.68–0.95 \)) and, when compared with the RT-PCR result, had good COVID-19 diagnostic performance with a sensitivity of 75%
Early identification of patients with COVID-19 is essential for treatment and viral control. Therefore, the search for alternative diagnostic biomarkers for COVID-19 is mandated in the context of asymptomatic and presymptomatic infection and the variable sensitivity of SARS-CoV-2 RT-PCR testing.8-12 We have assessed candidate biomarkers in those patients who present with suspected acute stroke and undergo immediate CTA. We have shown that an imaging feature, the presence or absence of apical GGO, which is simple to assess, is a reliable and accurate COVID-19 diagnostic biomarker. In contrast, all other contemporaneous demographic, clinical, and imaging features available at the time of CTA were not helpful in the early identification of COVID-19. Furthermore, we have shown that the same biomarker is a prognostic biomarker predictive of 30-day mortality. All our findings have not been reported previously.

RT-PCR testing was performed at or before CTA in 44% (47/106) of patients, and 23% (11/47) of tests had positive findings. SARS-CoV-2 RT-PCR testing has limitations as a reference standard due to the diagnostic performance of the assay and external factors related to sampling performance, location, and timing.11 Even with many health care systems now adopting routine RT-PCR screening on admission, there may be a relatively long processing time.11 Indeed, in our cohort, results were available in only 15% (7/47) of cases at the time of CTA, thus emphasizing the utility of any reliable alternative opportunistically derived diagnostic COVID-19 biomarkers.

Given that the presence of apical GGO was simple to assess and a reliable and accurate diagnostic biomarker for COVID-19, we examined whether patients with apical GGO, regardless of whether a RT-PCR test had been performed, also revealed useful information on admission. GGO was an independent predictor of increased 30-day mortality (18.0% versus 5.7%, P = .02; hazard ratio = 3.51 [95% CI, 1.42–8.66]; P = .006; Fig 2 and On-line Tables 5–7).

**DISCUSSION**

Table 1: Diagnostic accuracy of imaging biomarkers on CTA in determining patients tested for SARS-CoV-2 (n = 106)

<table>
<thead>
<tr>
<th>Presence of GGO</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
<th>PPV (95% CI)</th>
<th>NPV (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presence of GGO</td>
<td>75% (56–87)</td>
<td>88% (71–88)</td>
<td>58% (41–74)</td>
<td>90% (79–95)</td>
</tr>
<tr>
<td>Focal GGO</td>
<td>46% (29–64)</td>
<td>90% (81–95)</td>
<td>62% (59–81)</td>
<td>82% (72–89)</td>
</tr>
<tr>
<td>Bilateral GGO</td>
<td>57% (37–75)</td>
<td>82% (72–89)</td>
<td>53% (35–71)</td>
<td>84% (73–91)</td>
</tr>
<tr>
<td>Peripheral GGO</td>
<td>68% (49–82)</td>
<td>88% (79–94)</td>
<td>68% (48–83)</td>
<td>88% (79–94)</td>
</tr>
<tr>
<td>COVID-19-typical/in-determinate</td>
<td>64% (46–79)</td>
<td>92% (84–94)</td>
<td>77% (50–92)</td>
<td>88% (74–95)</td>
</tr>
</tbody>
</table>

**Note:**—PPV indicates positive predictive value; NPV, negative predictive value.

**Table 2: Multivariate analysis using clinical and imaging features to determine the likelihood of SARS-CoV-2 (n = 106)**

<table>
<thead>
<tr>
<th>Feature</th>
<th>OR (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infarct</td>
<td>0.47</td>
<td>0.25</td>
</tr>
<tr>
<td>Oxygen saturation</td>
<td>1.00</td>
<td>0.78</td>
</tr>
<tr>
<td>Presence of GGO</td>
<td>11.65</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

**With regard to total number of patients with confirmed SARS-CoV-2 (28/106), only the 3 most discriminant characteristics from the univariate analysis (P ≤ .05) were included. If all 6 variables were included, all 10 variables OR ≥ 3.51 [95% CI, 1.42–8.66], P = .006; Fig 2 and On-line Tables 5–7).**

(95% CI, 56–87) and a specificity of 81% (95% CI, 71–88) and OR = 11.65 (95% CI, 4.14–32.78; P < .001) on multivariate analysis. While the presence of GGO alone is the simplest feature to understand and measure, we determined that GGO subfeatures (peripheral, focal, or bilateral) or a descriptive grading system were more specific but less sensitive. The grading system gave the highest specificity of 92% (95% CI, 84–94).

**Apical GGO Cohort Characteristics**

We also examined whether apical GGO (On-line Figure B), regardless of RT-PCR results, revealed useful information (On-line Table 5). Patients with GGO versus patients without GGO, stroke parameters differed in patients with GGO (50/225) with a higher rate of carotid occlusion on CTA (16.0% versus 3.4%, P = .004) and a greater clinical deficit (mean NIHSS score, 6.2 versus 9.4; P = .02).

In terms of clinical features associated with pneumonia, patients with GGO more often had a cough (P = .002), fever (P = .004), a higher respiratory rate (P = .005), and lower oxygen saturation (P = .001). Patients with GGO had a higher mortality rate 18.0% (9/50) versus 5.7% (10/175) (P = .02), and survivors stayed longer in the hospital (3.8 versus 6.6 days, P = .004).

We performed a multivariate analysis (On-line Table 6) incorporating all demographic, clinical, and imaging features immediately available on hospital admission when univariate analysis (On-line Table 5) had shown a group comparison difference of P < .01. Carotid occlusion, subjective fever, and lower oxygen saturation showed an increased likelihood of GGO. Carotid occlusion and oxygen saturation were the most predictive features (OR = 6.82; 95% CI, 1.97–23.53; P = .002; OR = 0.81; 95% CI, 0.69–0.95; P = .009, respectively).

Biomarker group differences were not due to a difference in the craniocaudal extent of the lung included on CTA (Table 1 and On-line Table 5). Furthermore, during the limited range assessed (mean, 8.06 ± 2.5 cm), there was no correlation between this coronal measurement and the presence of GGO (point biserial correlation coefficient = 0.053); thus, we were unable to show an incentive to increase the extent of apical lung included during CTA.

The presence of GGO was an independent predictor of increased 30-day mortality (18.0% versus 5.7%, P = .02; hazard ratio = 3.51 [95% CI, 1.42–8.66]; P = .006; Fig 2 and On-line Tables 5–7).
The implication is that GGO may not be an entirely incidental finding in this cohort of patients with suspected acute stroke. We also noted that unlike patients grouped by RT-PCR results, survivors stayed in the hospital longer \( (P = .004) \), plausibly because of the morbidity associated with pneumonitis (or other causes because this is a multisystem disease).

The study most similar to ours analyzed 118 CTA studies performed as stroke investigations and found that 28% (33/118) had lung findings typical for COVID-19 and 93.9% (31/33) had a positive SARS-CoV-2 RT-PCR infection.31 Another small retrospective study showed apical lung abnormalities on cranio-cervical CTA in 10/17 (58.8%) patients with COVID-19 pneumonia whose diagnosis was unknown at the time of CT scanning.32 Again, these studies emphasize the importance of careful scrutiny of the lung apices. Our study sampled a greater number of patients than both of these, demonstrating the frequency of ground-glass opacification similar to that in the first study; however, it also included statistics on interrater reliability, diagnostic performance of the biomarker, and survival data, which were not included in either of these studies.

A further study analyzed 119 nonchest CT scans, including abdominal \( (n = 101) \) and cervical spine \( (n = 18) \) imaging.33 Fifty-two percent (62/119) of patients were suspected of having COVID-19 and underwent RT-PCR testing before the CT reading; 48% (57/119) were not suspected of having COVID-19. The presence of pneumonia was seen in 64% (76/119), leading to a diagnosis of COVID-19 in 37% (44/119). The prevalence of pneumonia was higher (64%) than the presence of apical GGO in our cohort (22%), plausibly due to a broader definition of COVID-19-typical abnormality and 102/119 patients (84%) undergoing abdominal imaging, including the lung bases. The lung bases likely yield more COVID-19-typical abnormalities than the apices, given the predilection for lower lobe and posterior segment involvement.15-18 The diagnostic reliability and accuracy metrics including IRR, sensitivity, and specificity were not reported.

The implications of our findings plausibly include earlier selection of the appropriate level of personal protective equipment and attendant staff numbers, triage to appropriate inpatient ward settings, self-isolation, and contact tracing.33 Guidance on selection of personal protective equipment often changes on the basis of available evidence, and risk stratification is the key to this in a number of health care settings.34,35 Biomarkers, such as a scan positive for GGO, should heighten awareness of a potential positive case, possibly changing staff personal protective equipment requirements (eg, from a fluid-repellant surgical mask to an FFP2 or N95 mask) and also directing a patient to a side room instead of an open ward, pending RT-PCR results. This patient group may additionally find it difficult to wear a mask, hence increasing the importance of staff protection. Our data therefore have important safety implications for daily clinical practice as well as prognostic information, given the increased mortality in those with COVID-19 shown in our cohort.

Our study has a number of strengths. It is multicenter and is the only study robustly assessing the apices for GGO. Its main limitation is its retrospective nature; however, no prospective studies exist in the literature relating to COVID-19 imaging. The use of the nonvalidated BSTI COVID-19 guidelines in some parts of the study may also be a limitation; however, no validated pulmonary scoring system yet exists for COVID-19 nor does this issue interfere with our conclusions.

CONCLUSIONS

This study demonstrates that the presence of apical GGO on carotid CTA in patients presenting with suspected acute stroke is a simple, reliable, and accurate diagnostic and prognostic COVID-19 biomarker. This can now be tested prospectively for further validation. These findings mandate vigilance in apical assessment by all radiologists and clinicians involved in acute stroke care, particularly relevant given the sensitivity of currently available SARS-CoV-2 RT-PCR testing.

ACKNOWLEDGMENTS

The authors acknowledge the South London Specialist Virology Centre, Viapath, Infections Sciences, in this study.

REFERENCES

1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/